We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Spot Urine Sample Evaluated for Renal Potassium Loss

By LabMedica International staff writers
Posted on 02 Dec 2020
Hypokalemia is characterized by low serum potassium concentrations. More...
Severe hypokalemia can be life threatening, and immediate potassium replacement is often required to prevent sudden cardiac arrest.

Initial identification of hypokalemia etiology is based on an estimate of urine potassium excretion during a 24-hr urine collection in the absence of potassium supplementation, but the utility of this approach in the emergency department is limited.

Endocrinologists at The Affiliated Hospital of Southwest Medical University (Luzhou, China) divided patients with hypokalemia were into two groups: 67 patients with hypokalemia caused by renal potassium loss and 63 patients with hypokalemia caused by extrarenal potassium loss. Arterial blood gases were measured with an ABL800 blood gas analyzer (Radiometer, Copenhagen, Denmark).

Urine potassium concentration (UK), urine creatinine concentration (UCr), urine potassium-creatinine ratio (UK/UCr), fractional excretion of potassium (FEK), transtubular potassium concentration gradient (TTKG), and 24-h urine potassium excretion (24 hUK-calculated) were derived from spot urine samples collected on admission, and were determined using automated methods on a 7170A automatic biochemistry analyzer (Hitachi Healthcare, Tokyo, Japan).

The scientists reported that patients with hypokalemia caused by renal potassium loss had significantly higher UK, UK/UCr, FEK, TTKG and 24 hUK-calculated compared to patients with hypokalemia caused by extrarenal potassium loss. FEK predicted renal potassium loss in hypokalemia with high accuracy at a cut-off of 9.29% (sensitivity, 80.6%; specificity, 85.7%). Patients with primary aldosteronism had significantly higher UK and TTKG compared to patients without primary aldosteronism. There were no significant differences in UK/UCr, FEK or 24 hUK-calculated between patients with primary aldosteronism and not primary aldosteronism. On the spot urine test, FEK showed the highest correlation with 24 hUK-actual during low or high dose potassium chloride infusion.

The authors concluded that prompt treatment with potassium chloride is required for patients with hypokalemia; 24 hUK-actual is not a suitable marker for predicting renal potassium loss in medical practice. Findings from this study suggest that a spot urine sample collected before potassium chloride therapy has utility for differentiating between renal and extrarenal potassium loss in hypokalemia. FEK from a spot urine sample represents a convenient and reliable parameter to predict renal potassium loss in patients with hypokalemia. The study will be published in the December, 2020 issue of the journal Clinica Chimica Acta.

Related Links:
The Affiliated Hospital of Southwest Medical University
Radiometer
Hitachi Healthcare



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.